NCT07625202 Creatine Supplementation During GLP-1a Therapy
| NCT ID | NCT07625202 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Saskatchewan |
| Condition | Sarcopenia |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2026-05-25 |
| Primary Completion | 2027-05-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2026-05-25 with a primary completion date of 2027-05-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
GLP-1 receptor agonists are effective for weight loss, but significant muscle mass is lost as a proportion of this weight loss. This study combines resistance-training and creatine supplementation to try to prevent this loss of muscle mass.
Eligibility Criteria
Inclusion Criteria: * Starting GLP-1 agonist therapy * 18 years of age or older Exclusion Criteria: * Positive answers to a screening questionnaire for physical activity safety (the Get Active Questionnaire)
Contact & Investigator
Philip Chilibeck, PhD
PRINCIPAL INVESTIGATOR
University of Saskatchewan
Frequently Asked Questions
Who can join the NCT07625202 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Sarcopenia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07625202 currently recruiting?
Yes, NCT07625202 is actively recruiting participants. Contact the research team at phil.chilibeck@usask.ca for enrollment information.
Where is the NCT07625202 trial being conducted?
This trial is being conducted at Saskatoon, Canada.
Who is sponsoring the NCT07625202 clinical trial?
NCT07625202 is sponsored by University of Saskatchewan. The principal investigator is Philip Chilibeck, PhD at University of Saskatchewan. The trial plans to enroll 40 participants.